Managing diabetes is now simpler and more convenient with new premixed insulin analogue



    - Available in Canada, NovoMix(R) 30 helps patients achieve blood glucose
    control -

    VANCOUVER, April 3 /CNW/ - Canadians with diabetes now have a new
treatment option, which controls blood glucose throughout the day and helps to
simplify and improve the management of the disease(1),(2). Now available in
Canada, NovoMix(R) 30 (biphasic insulin aspart) is a premixed insulin analogue
indicated for adults affected by diabetes that is a great option for people
who are having difficulty controlling their blood sugar using human insulin or
anti-diabetic pills, or are just starting to use insulin.
    Diabetes is an epidemic in this country that affects more than two
million Canadians. Ninety per cent of these people have type 2 diabetes.(3)
Diabetes is a serious condition that needs to be managed throughout a
lifetime. There is no cure, so using newer types of insulin that more closely
mimic the body's own insulin can help Canadians affected by diabetes achieve
long-term health. If left untreated or poorly managed, diabetes can lead to
heart disease, kidney disease and blindness.(4)
    "Many people with diabetes start taking insulin later than they should
because they believe that they are achieving blood glucose control when they
aren't. Poor control of blood glucose levels can lead to greater risk of
serious long-term complications," said Dr. Alex Leung, a family physician with
more than 20 years in diabetes care. "NovoMix(R) 30 combines a rapid-acting
and long-acting insulin, which can simplify the management of diabetes and
help people achieve their recommended glucose levels."
    In addition to long-term complications, people with diabetes also worry
about side effects like dizziness and disorientation that can occur when their
blood glucose is too low or they have too much insulin. These types of effects
are less likely with insulin analogues like NovoMix(R) 30.(5)
    People with diabetes take insulin because their bodies are unable to
produce insulin, or enough insulin, needed to manage blood sugar.
NovoMix(R) 30 contains two components -- a long-lasting insulin and a
rapid-acting insulin analogue that starts to work in 10 minutes -- in one
dose. This premixed combination closely mimics the body's own insulin by
providing a rapid initial blood glucose lowering effect needed right at
mealtimes, followed by a prolonged effect that controls blood glucose
throughout the day.
    "Insulin has been very effective in helping me manage my diabetes, but I
currently have to take insulin every night before bed, and at least 30 minutes
before every meal, which can be hit and miss especially when I eat out," said
Salma Ladak, who has been living with diabetes for more than 25 years. "The
availability of NovoMix(R) 30 means I can more easily control my blood sugar
with a less rigid schedule, and less worry about blood sugar lows. It will
make a significant difference in the way I feel about my diabetes."

    TYPE 2 DIABETES

    More than two million Canadians have diabetes, and this number is
expected to rise to more than three million by the end of the decade.(6)
Type 2 diabetes is the most common, affecting approximately 90 per cent of
Canadians with the disease.(7)
    Diabetes can lead to serious health complications, including increased
risk of heart disease, stroke, kidney disease, blindness, and amputation.(8)
The cost of diabetes to Canadian society is expected to rise to $19.2 billion
by 2020.(9)
    Lifestyle changes, including healthy eating and physical activity, can
prevent or delay the onset of type 2 diabetes.(10)

    NOVO NORDISK CANADA INC.

    Novo Nordisk is a healthcare company and a world leader in diabetes care
and biopharmaceuticals. Novo Nordisk manufactures and markets pharmaceutical
products and services that make a significant difference to patients, the
medical profession and society. Novo Nordisk's business is driven by the
Triple Bottom Line: a commitment to economic success, environmental soundness,
and social responsibility to employees and customers.
    The company's 80-year history of diabetes care innovation and achievement
originated in Canada where insulin was discovered. With headquarters in
Denmark, Novo Nordisk has more than 23,500 full-time employees in 79
countries, and markets its products in 179 countries. Novo Nordisk's B shares
are listed on the stock exchanges in Copenhagen and London. Its ADRs are
listed on the New York Stock Exchange under the symbol 'NVO'. For more
information, visit www.novonordisk.com.

    A VNR will be available at 11:00 and 14:30 EST at the following
coordinates:

    11:00 - 11:30 and 14:30-15:00 Eastern
    Anik F2, C-Band, Transponder 1B @ 111.1 West
    Vertical Polarization, D/L Freq. 3740MHz. Channel 2
    Audio subcarriers 6.8 left, 6.2 right

    
    ------------------------------------
    (1)  Boehm B, et al. European Journal of Internal Medicine 2004;15:496
    (2)  Raskin P, Allen E, Hollander P, et. al. Initiating Insulin Therapy
         in Type 2 Diabetes: A comparison of biphasic and basal insulin
         analogs. Diabetes Care 2005; 28.
    (3)  Canadian Diabetes Association. The Prevalence and costs of
         Diabetes. Available at:
         http://www.diabetes.ca/Section_About/prevalence.asp.
         Accessed on: January 16, 2007.
    (4)  Ibid
    (5)  Boehm B, et al. European Journal of Internal Medicine 2004;15:496
    (6)  Canadian Diabetes Association. The Prevalence and costs of Diabetes.
         Available at: http://www.diabetes.ca/Section_About/prevalence.asp.
         Accessed on: January 16, 2007.
    (7)  Canadian Diabetes Association. Diabetes Facts. Available at:
         http://www.diabetes.ca/Section_About/thefacts.asp.
         Accessed on: January 16, 2007.
    (8)  Canadian Diabetes Association. The Prevalence and costs of Diabetes.
         Available at: http://www.diabetes.ca/Section_About/prevalence.asp.
         Accessed on: January 16, 2007.
    (9)  Ibid
    (10) Canadian Diabetes Association. Diabetes Facts. Available at:
         http://www.diabetes.ca/Section_About/thefacts.asp.
         Accessed on: January 16, 2007.
    





For further information:

For further information: Dana Allison, Jennifer Goode, Edelman, (416)
979-1120, ext. 318, 230, Dana.Allison@edelman.com, Jennifer.Goode@edelman.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890